Vitiligo

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

The FDA asked the company to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

Amit G. Pandya, MD, FAAD, shares advice for the detection and treatment of vitiligo.

Dr Amit G. Pandya discusses novel drugs in the pipeline for the treatment of vitiligo.

An expert dermatologist shares insight on the differences in response to vitiligo treatment based on different body parts being treated.

Amit G. Pandya, MD, FAAD, reviews the goals of therapy for patients with vitiligo and considers factors that drive treatment decisions.

Dr Amit G. Pandya discusses the role of an HCP in motivating patients and setting their expectations for successfully managing and treating vitiligo.

An expert dermatologist comments on the real-world impact of vitiligo and how it can affect a patient’s quality of life.

A systematic review of several skin diseases including vitiligo and acne supported the need to evaluate vitamin E status in affected patients.

Amit G. Pandya, MD, FAAD, provides insight on the pathogenesis and differential diagnoses of vitiligo.

Dr. Moody speaks to how these E/M code changes affect billing documentation and patient care.

Results from the RELIEVE-AD study were consistent with patient-reported outcomes in clinical trials.

Apremilast is now the first and only treatment approved in adult patients with plaque psoriasis across all severities.

Both PEARL 1 and PEARL 2 enrolled over 2000 adults and adolescents patients selected from 48 countries.

Dr. Rosmarin details the TruE-V clinical trial, and speaks to what could eventually be the first FDA approved medicine for vitiligo.

Topical pimecrolimus 1% treatment had unsatisfactory results, while combination microneedling and topical pimecrolimus treatment showed a favorable outcome.

Prominent dermatologists detail how a biased literature, a lack of education, accessibility issues, and historical wrongdoings have all influenced the study of skin of color.

Investigators believe this could be a good option for patients who did not respond to a first-line biologic, though further research is required.

Investigators added that clinical condition at the time of vaccination and biologic treatment did not influence the humoral response in the enrolled patients.

Half of all cases of vitiligo occur in childhood, and accessibility to therapy has been an ongoing issue.

According to investigators, no previous studies had investigated the expression of IL-38 in patients with vitiligo.

A litany of research has begun to shape the potential benefit of UV treatment for the skin disorder. Experts share what more needs to be known.

Nearly 70% of all vitiligo patients included in the study remained pigmented after systemic immunomodulatory treatment, with no evidence of recurrence of the disease.